Düzenleyici B Hücreleri ve Kanserdeki Rolü

ERDAL, BERNA; YILMAZ, Bahar

doi:10.31832/smj.711179

Düzenleyici B Hücreleri ve Kanserdeki Rolü

Berna Erdal, (Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Tekirdağ, Türkiye)

Bahar Yılmaz (Tekirdağ Namık Kemal Üniversitesi, Sağlık Bilimleri Enstitüsü, Tümör Biyolojisi ve İmmünolojisi Anabilim Dalı, Tekirdağ, Türkiye)

Sakarya Tıp Dergisi

1 0

Yıl: 2020 Cilt: 10 Sayı: 2 Sayfa Aralığı: 326 - 333 Metin Dili: Türkçe DOI: 10.31832/smj.711179 İndeks Tarihi: 23-05-2021

Düzenleyici B Hücreleri ve Kanserdeki Rolü

Öz:

Hümoral immün yanıt elemanı olan B hücreleri antikor üretiminden sorumlu hücrelerdir. Progenitör B hücreleri, kemik iliğinde olgunlaşırlar. B hücrelerinin yüzeyindeantijen reseptörleri, immünglobulin reseptörleri, adhezyon molekülleri ve Major Doku Uygunluk Kompleksi (MHC) molekülleri bulunur. Bu hücrelerin antijene bağlanmayeteneğinin gelişmesi sekonder lenfoid organlarda lenf foliküllerinin kendine özgü mikroçevresinde, T hücrelerine bağımlı olarak gerçekleşmektedir. Antijenik biruyarım sonucunda aktive olan B hücreleri plazma hücrelerine ve sonrasında bellek B hücrelerine farklılaşırlar. Düzenleyici B (Breg) hücreleri, immünolojik toleransıdestekleyen B hücrelerinin alt grubu olan immünsüpresif hücrelerdir. İnterlökin-10 (IL-10), IL-35 ve transforme edici büyüme faktörü beta (TGF-β) üreten Breg hücreleri,T hücrelerinin ve diğer pro-inflamatuar lenfositlerin ifadesini engelleyerek otoimmün patolojiyi baskılamaktadır. Son çalışmalar, farklı inflamatuar ortamların farklı Breghücre popülasyonlarını uyardığını göstermiştir. Hem insanlarda hem de hayvanlarda inflamasyon, transplantasyon, otoimmünite ve kanser modellerinde çeşitli Bregalt grupları tanımlanmıştır. Breg'lerin tümör oluşumunu baskıladığı ve terapötik amaçla kullanılabileceği yapılan farklı çalışmalar ile gösterilmiştir. Bu derlemede, Breghücrelerinin işlevlerine ve kanserdeki rollerine genel bir bakış sunulması amaçlanmaktadır.

Anahtar Kelime:

Regulatory B Cells and Role In Cancer

Öz:

B cells, the humoral immune response element, are the cells responsible for antibody production. Progenitor B cells, mature in bone marrow. The surface of B cells contains antigen receptors, immunoglobulin receptors, adhesion molecules and Major Histocompatibility Complex (MHC) molecules. The development of the ability of these cells to bind antigen occurs depending on T cells in secondary lymphoid organsin the specific microenvironment of lymphfollicles. As a result of an antigenic stimulation, activated B cells differentiate into plasma cell and then memory B cells. Regulatory B (Breg) cells, a subset of B cells, are immuno suppressive cells that support immunological tolerance. Interleukin (IL)-10, IL-35, and transforming growth factor beta (TGF-β) producing Breg cells inhibit auto immune pathology by preventing the expression of T cells and other pro-inflammatory lymphocytes. Recent studies have shown that different inflammatory environments induce different Breg cell populations. Various Breg subsets have been identified in inflammation, transplantation, autoimmunity and cancer models in both humans and animals. It has been shown in different studies that bregs suppress tumor formation and can be used for therapeutic purposes. In this review, it is aimed to provide an over view of functions and roles in cancer of Breg cells.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. You Chao D, Jıxın Z, Jun-Fa X. Regulatory B Cells İn İnfectious Disease. Molecular Medıcıne Reports 2017;16:3-10.
2. Rowa YA. Regulatory B cells: Development, phenotypes, functions, and role in transplantation. Immunological Reviews 2019;00:1–16.
3. Rosser EC, Mauri C. Regulatory B cells: origin, phenotype and function. Immunity 2015;42(4):607‐612.
4. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012;30:221‐241.
5. Fitzgerald DC, et. Al. Suppression of autoimmune infl ammation of the central nervous system by interleukin 10 secreted by interleukin 27–stimulated T cells. Nat. Immunol. 2007;8(12):1372-1379.
6. Medzhitov R. Origin and physiological roles of infl ammation. Nature 2008;454:428–435. 7. Nathan C, Ding A. Non resolving infl ammation. Cell 2010;140:871–882.
8. Maynard CL, Weaver CT. Diversity in the contribution of interleukin‐10 to T‐cell‐mediated immune regulation. Immunol. Rev. 2008;226(1):219–233.
9. Saraiva M, Christensen JR, Veldhoen M, Murphy TL, Murphy KM, O’Garra A. Interleukin-10 production by Th 1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 2009;31(2):209–219.
10. Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligand activated plasma cytoid dendritic cells. J. Exp. Med. 2002;195(6):695–704.
11. Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ. Mastcell–derivedi nterleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat. Immunol.2007;8(10):1095.
12. Moore KW, de Waal Malefyt R, Coff man RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol.2001;19(1):683–765.
13. Blair PA, Noreña Y, Flores-Borja F, Rawlings D.J, Isenberg D.A, Ehrenstein M.R, et al. CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010;32(1):129– 140.
14. Iwata Y, Matsushita T, Horikawa M, DiLillo DJ, Yanaba K, Venturi G.M, et al. Characterization of a rare IL-10 competent B-cell subset in humans that parallels Mouse regulatory B10 cells. Blood 2011;117(2):530–541.
15. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells andrestrain T H-17 cell–mediated pathology. Nat. Immunol.2007;8(12):1390-1397.
16. Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, et al. Interleukins 27 and 6 induce STAT3 mediated T cell production of interleukin 10. Nat. Immunol.2007;8(12):1363-1371.
17. Delves PJ, Roitt IM. Th e immune system. First of two parts. N Engl J Med. 2000;6,343(1):37- 49.
18. Öztürk E. B hücre aktivasyonu ve antikor üretimi. Türkdem2013;47:Özel Sayı 1: 24-7.
19. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing Immunity Perspective regulatory B cell subset characterized by CD1d upregulation. Immunity2002;16: 219–230.
20. Lai G, Nakayama Y, Burrell BE, Ding Y, Bromberg JS. Non-humoral functions of B cells is required for tolerance. Am J Transplant2011;11: 105.
21. İlhan F, Taş SK. Organ Nakillerinde Regülatör B Hücrelerin Rolü. Turkiye Klinikleri J Immun Allergy-Special Topics 2013;6(2):29-35.
22. Adams AB, Newell KA. B cells in clinical transplantation tolerance. Semin Immunol. 2012;24 (2):92-5.
23. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell eff ect or cytokines: a role in immune regulation. J Immunol. 2004;172(6):3422-3427.
24. Wortel CM, Heidt S. Regulatory B cells: Phenotype, function and role in transplantation. Transplant Immunology 2017; 41:1–9.
25. Valizadeh A, Sanaeib R, Rezaeia N, Azizid G, Fekrvanda S, Aghamohammadia A, et al. Potential role of regulatory B cells in immunological diseases.Immunology Letters 2019;215:48–59.
26. Carter NA, Vasconcellos R, Rosser EC, Tulone C, Muñoz-Suano A, Kamanaka M, et al. Mice lacking endogenous IL-10–producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th 1/Th 17 but a decrease in regulatory T cells. J. Immunol. 2011;186(10):5569–5579.
27. Gray M, Miles K, Salter D, Gray D, Savill J. Apoptotic cells protect mice from autoimmune infl ammation by the induction of regulatory B cells, Proc. Natl. Acad. Sci. U. S. A. 2007;104 (35):14080–14085.
28. Zhang X, Deriaud E, Jiao X, Braun D, Leclerc C, Lo-Man R. Type I interferons protect neo nates from acute infl ammation through interleukin 10–producing B cells. J. Exp. Med. 2007;204(5):1107–1118.
29. Lundy SK, Fox D.A. Reduced Fas ligand-expressing splenic CD5+ B lymphocytes in severe collagen-induced arthritis. Arthritis Res. Th er. 2009;11(4):R128.
30. Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, et al. Regulatory B cells are enriched with inthe IgM memory and transitional subsets in healthy donors but are deficient in chronic GVH. Blood. 2014;124(13): 2034–2045.
31. Lino AC, Lampropoulou V, Welle A, Joedicke J, Pohar J, Simon Q, et al. LAG-3 inhibitory receptor expression identifies immuno suppressive natural regulatory plasma cells. Immunity 2018;49(1):120–133
32. Ding Q, Yeung M, Camirand G, Zeng Q, Akiba H, Yagita H, et al. Regulatory B cells are identified by expression of TIM-1 and can be induce dthrough TIM-1 ligation topromote tol- eranceinmice. J. Clin. Invest. 2011;121(9):3645-3656.
33. Matsumoto M, Baba A, Yokota T, Nishikawa H, Ohkawa Y, Kayama H, et al. Interleukin-10-producing plasmablasts exert regulatoryfunction in autoimmune infl ammation. Immunity 2014;41(6):1040–1051.
34. Lindner S, Dahlke K, Sontheimer K, Hagn M, Kaltenmeier C, Barth T.F, et al. Interleukin 21–induced granzyme B–expressing B cells infiltrate tumors and regulate T cells. Cancer Res. 2013;73(8):2468–2479.
35. Van de Veen W, Stanic B, Yaman G, Wawrzyniak M, Söllner S, Akdis D.G, et al. IgG4 production is confined tohuman IL10–producing regulatory B cells that suppress antigen-specific immune responses. J. Allergy Clin. Immunol. 2013;131(4):1204–1212.
36. Rafei M, Hsieh J, Zehntner S, Li M, Forner K, Birman E, et al. A granulocyte-macrophage colony–stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat. Med. 2009;15(9):1038-1045.
37. Khan AR, Hams E, Floudas A, Sparwasser T, Weaver CT, Fallon PG. PD-L1hi B cells are critical regulators of humoral immunity, Nat. Commun. 2015;6: 5997.
38. Watanabe R, Ishiura N, Nakashima H, Kuwano Y, Okochi H, Tamaki K. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacer bates systemic autoimmunity. J. Immunol. 2010;184(9):4801–4809.
39. Kalampokis I, Yoshizaki A, Tedder TF. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res. Th er. 2013;15(1): S1.
40. Xiao S, Brooks CR, Sobel RA, Kuchroo VK. Tim-1 is essential for inductionand maintenance of IL-10 in regulatory B cells and their regulation of tissue infl ammation. J. Immunol. 2015;194(4):1602–1608.
41. Gasperi C, Melms A, Schoser B, Zhang Y, Meltoranta J, Risson V, et al. Anti-agrin auto antibodies in myas then iagravis. Neurology 2014;82(22):1976–1983.
42. Sayi A, Kohler E, Toller I.M, Flavell R.A, Muller W, Roers A, et al. TLR-2-activated B cells suppress Helicobacter-induced pre neoplastic gastric immunopathology by inducing T regulatory-1 cells. J Immunol. 2011;186:878-890.
43. Chesneau M, Michel L, Dugast E, Chenouard A, Baron D, Pallier A. Tolerant kidney transplant patients produce B cells with regulatory properties. J. Am. Soc. Nephrol. 2015;26(10):2588–2598.
44. Zeng Q, Ng Y.H, Singh T, Jiang K, Sheriff KA, Ippolito R. B cells mediate chronic allo graft rejectionin dependently of antibody production. J. Clin. Invest. 2014;124(3):1052–1056.
45. Maseda D, Smith SH, DiLillo DJ, Bryant JM, Candando KM, Weaver CT. Regulatory B10 cells diff erentiate into antibody-secreting cells aft er transient IL-10 production in vivo. J. Immunol. 2012;188(3):1036–1048.
46. Deng S, Moore DJ, Huang X, Lian MM, Mohiuddin M, Velededeoglu E. Cuttingedge: trans plant tolerance induced by anti-CD45RB requires B lymphocytes. J. Immunol. 2007;178 (10):6028–6032.
47. Tarique M, Naz H, Kurra SV, Naqvi RA, Saini C, Rai R, et al. IL-10-producing regulatory B cells transformed CD4+CD25- into Tregs and enhanced regulatory T cells function in human leprosy. Front. Immunol. 2018;9: ID1636.
48. Zhao Y, Shen M, Feng Y, He R, Xu X, Xie Y, et al. Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway. Oncotarget 2018;9(19):14803-14814.
49. Lee-Chang C, Bodogai M, Martin-Montalvo A, Wejksza K, Sanghvi M, Moaddel De Cabo R, et al. Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells, J. Immunol. 2013;191(8):4141–4151.
50. Mehdipour F, Razmkhah M, Hosseini A, Bagheri M, Safaei A, Talei AR, et al. B regulatory phenotype in non‐metastatic lymphnodes of node‐positive breast cancer patients. Scand. J. Immunol. 2016;83(3):195–202.
51. Lee-Chang C, Bodogai M, Martin-Montalvo A, Wejksza K, Sanghvi M, Moaddel De Cabo R, et al. Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells, J. Immunol. 2013;191(8):4141–4151.
52. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int. J. Cancer 2010;127(12):2893–2917.
53. Shi J, Li S, Zhou Y, Wang L, Wen J, Wang Y, et al. Perio perative changes in peripheral regulatory B cells of patients with esophageal cancer. Mol. Med. Rep. 2014;10(3):1525–1530.
54. Aravalli RN, Cressman EN, Steer CJ. Cellular and molecular mechanisms of hepato cellular carcinoma: an update. Arch. Toxicol. 2013;87(2):227–247.
55. Shao Y, Lo CM, Ling C, Liu XB, Ng KTP, Chu ACY, et al. Regulatory B cells accelerate hepato cellular carcinoma progressionvia CD40/CD154 signaling pathway, Cancer Lett. 2014;355(2):264–272.
56. Meucci S, Keilholz U, Tinhofer I, Ebner OA. Mutation allo adand mutational patterns in relation to age in head and neck cancer. Oncotarget 2016;7: 69188–69199.
57. Ferris RL, Blumenschein GJ, Fayette J. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856–1867.
58. Jeske SS, Brand M, Ziebart A. Adenosine-producing regulatory B cells in head and neck cancer. Cancer Immunol Immuno ther. 2020.
59. Wardak S. Human papillomavirus (HPV) and cervical cancer. Medycyna Doświadczalna i Mikrobiologia 2016;68(1):73–84.
60. Chen Z, Zhu Y, Du R, Pang N, Zhang F, Dong D, et al. Regulatory B Cells in the Progression of Cervical Cancer. Hindawi Mediators of Infl ammation2019;Article ID 6519427.
61. Kim R, Emi M, Tanabe K. Cancer immuno editing from immune surveillance to immune escape. Immunology 2007;121:1–14

APA	ERDAL B, YILMAZ B (2020). Düzenleyici B Hücreleri ve Kanserdeki Rolü. , 326 - 333. 10.31832/smj.711179
Chicago	ERDAL BERNA,YILMAZ Bahar Düzenleyici B Hücreleri ve Kanserdeki Rolü. (2020): 326 - 333. 10.31832/smj.711179
MLA	ERDAL BERNA,YILMAZ Bahar Düzenleyici B Hücreleri ve Kanserdeki Rolü. , 2020, ss.326 - 333. 10.31832/smj.711179
AMA	ERDAL B,YILMAZ B Düzenleyici B Hücreleri ve Kanserdeki Rolü. . 2020; 326 - 333. 10.31832/smj.711179
Vancouver	ERDAL B,YILMAZ B Düzenleyici B Hücreleri ve Kanserdeki Rolü. . 2020; 326 - 333. 10.31832/smj.711179
IEEE	ERDAL B,YILMAZ B "Düzenleyici B Hücreleri ve Kanserdeki Rolü." , ss.326 - 333, 2020. 10.31832/smj.711179
ISNAD	ERDAL, BERNA - YILMAZ, Bahar. "Düzenleyici B Hücreleri ve Kanserdeki Rolü". (2020), 326-333. https://doi.org/10.31832/smj.711179

APA	ERDAL B, YILMAZ B (2020). Düzenleyici B Hücreleri ve Kanserdeki Rolü. Sakarya Tıp Dergisi, 10(2), 326 - 333. 10.31832/smj.711179
Chicago	ERDAL BERNA,YILMAZ Bahar Düzenleyici B Hücreleri ve Kanserdeki Rolü. Sakarya Tıp Dergisi 10, no.2 (2020): 326 - 333. 10.31832/smj.711179
MLA	ERDAL BERNA,YILMAZ Bahar Düzenleyici B Hücreleri ve Kanserdeki Rolü. Sakarya Tıp Dergisi, vol.10, no.2, 2020, ss.326 - 333. 10.31832/smj.711179
AMA	ERDAL B,YILMAZ B Düzenleyici B Hücreleri ve Kanserdeki Rolü. Sakarya Tıp Dergisi. 2020; 10(2): 326 - 333. 10.31832/smj.711179
Vancouver	ERDAL B,YILMAZ B Düzenleyici B Hücreleri ve Kanserdeki Rolü. Sakarya Tıp Dergisi. 2020; 10(2): 326 - 333. 10.31832/smj.711179
IEEE	ERDAL B,YILMAZ B "Düzenleyici B Hücreleri ve Kanserdeki Rolü." Sakarya Tıp Dergisi, 10, ss.326 - 333, 2020. 10.31832/smj.711179
ISNAD	ERDAL, BERNA - YILMAZ, Bahar. "Düzenleyici B Hücreleri ve Kanserdeki Rolü". Sakarya Tıp Dergisi 10/2 (2020), 326-333. https://doi.org/10.31832/smj.711179